Elez, ElenaGomez-España, Maria AuxiliadoraGravalos, CristinaGarcia-Alfonso, PilarOrtiz-Morales, Maria JoseLosa, FerranDiaz, Inmaculada AlesGraña, BegoñaToledano-Fonseca, MartaValladares-Ayerbes, ManuelPolo, EduardoSalgado, MercedesMartinez de Castro, EvaSafont, Maria JoseSalud, AntonietaRuiz-Casado, AnaTabernero, JosepRiesco, Maria Del CarmenRodriguez-Ariza, AntonioAranda, Enrique2023-05-032023-05-032021-11-09Élez E, Gómez-España MA, Grávalos C, García-Alfonso P, Ortiz-Morales MJ, Losa F, et al. Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial. Br J Cancer. 2022 Apr;126(6):874-880http://hdl.handle.net/10668/19521Aflibercept is an antiangiogenic drug against metastatic colorectal cancer (mCRC) combined with 5-fluorouracil/leucovorin/irinotecan (FOLFIRI); however, no antiangiogenic biomarker has yet been validated. We assessed aflibercept plus FOLFIRI, investigating the biomarker role of baseline vascular endothelial growth factor A (VEGF-A) and angiotensin-converting enzyme (ACE). Phase II trial in oxaliplatin-treated mCRC patients who received aflibercept plus FOLFIRI. The reported 135 ng/mL ACE cut-off was used and ROC analysis was performed to assess the optimal VEGF-A cut-off for progression-free survival (PFS). Overall survival (OS), time to progression (TTP), time to treatment failure (TTF), overall response rate (ORR) and disease control rate (DCR) were also assessed. In total, 101 patients were followed for a median of 12 (6-17) months. The 1941 pg/mL VEGF-A was an optimal cut-off, with a longer median PFS when VEGF-A was This study supports aflibercept plus FOLFIRI benefits, suggesting VEGF-A as a potential biomarker to predict better outcomes.enBiomarkersColorectal neoplasmsFluorouracilVascular endothelial growth factor AAntineoplastic combined chemotherapy protocolsBiomarkersCamptothecinColorectal neoplasmsFluorouracilHumansIrinotecanLeucovorinReceptors, vascular endothelial growth factorRecombinant fusion proteinsVascular endothelial growth factor Aresearch article34937947open accessBiomarcadoresFactor A de crecimiento endotelial vascularNeoplasias colorrectalesProteínas recombinantes de fusiónProtocolos de quimioterapia combinada antineoplásicaLeucovorinaReceptores de factores de crecimiento endotelial vascular10.1038/s41416-021-01638-w1532-1827PMC8927487https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927487https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927487/pdf